Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: Dissociation of complement activation and neutropenia from neutrophil degranulation

Journal of the American Society of Nephrology

Volumn 7, Issue 2, 1996, Pages 234-241

  Böhler, Joachim ^a   Schollmeyer, Peter ^a   Dressel, Beate ^a   Dobos, Gustav ^a   Hörl, Walter H ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Biocompatibility; Calcium; Cuprophane; Granulocytopenia; Polymethylmethacrylate

Indexed keywords

CALCIUM; CITRIC ACID; COMPLEMENT COMPONENT C3A; CUPROPHANE; ELASTASE; LACTOFERRIN; POLY(METHYL METHACRYLATE);

ADULT; ARTICLE; BIOCOMPATIBILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGRANULATION; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALE; NEUTROPENIA; NEUTROPHIL; PRIORITY JOURNAL;

EID: 0029881430     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/asn.v72234     Document Type: Article

References (35)

1. Kaplow LS, Goffinet JA: Profound neutropenia during the early phase of hemodialysis. JAMA 1968;203:1135-1137.
2. Chenoweth DE: The properties of human C5a anaphylatoxin. The significance of C5a formation during hemodialysis. Contrib Nephrol 1987;59:51-71.
3. Craddock PR, Fehr J, Dalmasso AP, Brigham KL, Jacob HS: Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest 1977;59:879-888.
4. Cheung AK: Biocompatibility of hemodialysis membranes [Review]. J Am Soc Nephrol 1990;1:150-161.
5. 2 integrins are required for neutrophil degranulation induced by hemodialysis membranes. Kidney Int 1993;43:649-660.
6. Hörl WH, Schäfer RM, Heidland A: Effect of different dialyzers on proteinases and proteinase inhibitors during hemodialysis. Am J Nephrol 1985;5:320-326.
7. Böhler J, Donauer K, Köster W, Schollmeyer PJ, Wieland H, Hörl WH: Biocompatibility of four plasmapheresis membranes in patients treated for hypercholesterolemia. Am J Nephrol 1991;11:479-485.
8. Haag-Weber M, Mai B, Deppisch R, Göhl H, Hörl WH: Studies of biocompatibility of different dialyzer membranes: Role of complement system, intracellular calcium and inositol-triphosphate. Clin Nephrol 1994;41: 245-251.
9. Haag-Weber M, Schollmeyer P, Hörl WH: Granulocyte activation during haemodialysis in the absence of complement activation: Inhibition by calcium channel blockers. Eur J Clin Invest 1988;18:380-385.
10. Haag-Weber M, Mai B, Hörl WH: Effect of hemodialysis on intracellular calcium in human polymorphonuclear neutrophils. Miner Electrolyte Metab 1992;18:151-155.
11. Böhler J, Donauer J, Birmelin M, Schollmeyer PJ, Hörl WH: Mediators of complement-independent granulocyte activation during haemodialysis: Role of calcium, prostaglandins and leukotrienes. Nephrol Dial Transplant 1993;8:1359-1365.
12. Hetherington SV, Spitznagel JK, Quie PG: An enzyme-linked immunoassay (ELISA) for measurement of lactoferrin. J Immunol Methods 1983;65:183-190.
13. Möllering H, Gruber W: Determination of citrate with citrate lyase. Anal Biochem 1966;17:369-376.
14. Hakim RM, Wingard RL, Parker RA: Effect of dialysis membrane in the treatment of patients with acute renal failure. N Engl J Med 1994;331:1338-1342.
15. Himmelfarb J, Ault KA, Holbrook D, Leeber DA, Hakim RM: Intradialytic granulocyte reactive oxygen species production: a prospective, crossover trial. J Am Soc Nephrol 1993;4:178-186.
16. Hörl WH, Steinhauer HB, Schollmeyer P: Plasma levels of granulocyte elastase during hemodialysis: Effects of different dialyzer membranes. Kidney Int 1985;28:791-796.
17. Schäfer RM, Huber L, Gilge U, Bausewein K, Vienken J, Heidland A: Clinical evaluation of a new high-flux cellulose acetate membrane. Int J Artif Organs 1989;12:85-90.
18. Hörl WH, Riegel W, Schollmeyer P, Rautenberg W, Neumann S: Different complement and granulocyte activation in patients dialyzed with PMMA dialyzers. Clin Nephrol 1986;25:304-307.
19. Pinnick RV, Wiegmann TB, Diederich DA: Regional citrate anticoagulation for hemodialysis in the patient at high risk for bleeding. N Engl J Med 1983;308:258-261.
20. Janssen MJ, Huijgens PC, Bouman AA, Oe PL, Donker AJ, van der Meulen J: Citrate versus heparin anticoagulation in chronic haemodialysis patients. Nephrol Dial Transplant 1993;8:1228-1233.
21. Mehta RL, McDonald BR, Aguilar MM, Ward DM: Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 1990;38:976-981.
22. Janssen MJ, Huijgens PC, Bouman AA, Oe PL, van der Meulen J: Citrate anticoagulation and divalent cations in hemodialysis. Blood Purif 1994;12:308-316.
23. Lew DP: Receptor signalling and intracellular calcium in neutrophil activation. Eur J Clin Invest 1989;19:338-346.
24. Wiegmann TB, MacDougall ML, Diederich DA: Dialysis leukopenia, hypoxemia, and anaphylatoxin formation: effect of membrane, bath, and citrate anticoagulation. Am J Kidney Dis 1988;11:418-424.
25. Cheung AK, Faezi-Jenkin B, Leypoldt JK: Effect of thrombosis on complement activation and neutrophil degranulation during in vitro hemodialysis. J Am Soc Nephrol 1994;5:110-115.
26. Leculier C, Couprie N, Adeleine P, Leitienne P, Francina A, Richard M: The effects of high molecular weight-and low molecular weight-heparins on superoxide ion production and degranulation by human polymorphonuclear leukocytes. Thromb Res 1993;69:519-531.
27. Hörl WH, Feinstein EI, Wanner C, Frischmuth N, Gösele A, Massry SG: Plasma levels of main granulocyte components during hemodialysis. Comparison of new and reused dialyzers. Am J Nephrol 1990;10:53-57.
28. Neveceral P, Markert M, Wauters JP: Role of protein adsorption on haemodialysis-induced complement activation and neutrophil defects. Nephrol Dial Transplant 1995;10:372-376.
29. Böhler J, Donauer J, Schollmeyer P, Hörl WH: Blood flow dependent granulocyte activation in membranes with and without complement activation. Adv Exp Med Biol 1991;297:215-224.
30. Papatheofanis FJ, Barmada R: Polymorphonuclear leukocyte degranulation with exposure to polymethylmethacylate nanoparticles. J Biomed Mater Res 1991; 25:761-771.
31. Alexiewicz JM, Smogorzewski M, Klin M, Akmal M, Massry SG: Effect of treatment of hemodialysis patients with nifedipine on metabolism and function of polymorphonuclear leukocytes. Am J Kidney Dis 1995;25:440-444.
32. Vanholder R, Ringoir S, Dhondt A, Hakim R: Phagocytosis in uremic and hemodialysis patients: A prospective and cross sectional study. Kidney Int 1991;39:320-327.
33. Ward RA, McLeish KR: Polymorphonuclear leukocyte oxidative burst is enhanced in patients with chronic renal insufficiency. J Am Soc Nephrol 1995;5:1697-1702.
34. 2+]i and carbohydrate metabolism of PMNL of dialysis patients. Kidney Int 1995;47:1741-1745.
35. 3 or calcium channel blocker. Am J Nephrol 1993;13:467-472.